Clinical Trials on Primary Immunodeficiency Diseases (PID)

Total 54063 results

Technische Universität Dresden
GWT-TUD GmbH

Completed

Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study (SIGNS)

Primary Immunodeficiency (PID) | Secondary Immunodeficiency (SID) | Neurological Autoimmune Disease

Germany
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
Shire

Completed

Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID) (IG-TATRY)

Primary Immunodeficiencies (PID)

Poland
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Primary Immunodeficiency Diseases (PID)

Canada
Takeda

Recruiting

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Primary Immunodeficiency Diseases (PID)

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Octapharma

Completed

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID)

France
Children's National Research Institute

Recruiting

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC)

Viral Infection | Hematopoietic Stem Cell Transplantation (HSCT) | Primary Immunodeficiency Disorders (PID)

United States
National Institute of Allergy and Infectious Diseases...
University of Pittsburgh; PPD

Completed

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant (BOLT-BMT)

Primary Immunodeficiency | PID

United States
Baxalta now part of Shire

Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Primary Immunodeficiency Diseases (PID) | Hypogammaglobulinemia | Agammaglobulinemia

Finland, Sweden
BriovaRx Infusion Services
Bio Products Laboratory (BPL)

Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Primary Immunodeficiency Disease (PIDD)

United States
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
Octapharma

Completed

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Primary Immunodeficiency

United Kingdom, Australia, Germany, Italy
University Hospital, Strasbourg, France

Completed

Severe PID With Lymphoproliferation and Neutropenia (DICEP)

Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)

France
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Paul Szabolcs

Recruiting

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC (PRO-RIC)

Congenital Bone Marrow Failure Syndromes | Inflammatory Conditions | Primary Immunodeficiency (PID) | Inherited Metabolic Disorders (IMD) | Hereditary Anemias

United States
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
Takeda

Completed

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Primary Immunodeficiency Disease

Japan
Octapharma

Completed

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) (NGAM-05)

Primary Immunodeficiency Disease

United States
National Cancer Institute (NCI)

Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
Azidus Brasil
Boya Bio Pharmaceutical Group Co Ltd

Not yet recruiting

Efficacy and Safety and Pharmacokinetics of Boya IVIG (Boya)

Primary Immunodeficiency Disease
Azidus Brasil
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG (Imunoforte)

Primary Immunodeficiency Disease
University of Zurich
University Hospital, Geneva; University of Lausanne; University of Bern; University... and other collaborators

Unknown

Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland

Primary Immunodeficiency Disease

Switzerland
Therapure Biopharma Inc

Unknown

Study of PlasmaCap IG in Adults and Children With PIDD

Primary Immune Deficiency Diseases (PIDD)

United States, Canada
Octapharma

Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Primary Immunodeficiency

United States, Canada
Assiut University

Completed

Minipooled-IVIG in Primary Immunodeficiency Disease

Primary Immunodeficiency

Egypt
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Grifols Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency (KIDS)

Primary Immunodeficiency

United States
CHU de Reims

Unknown

Tolerance and Patients' Satisfaction With IGHy

Secondary or Primary Immunodeficiency

France
Gazi University

Recruiting

Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency

Primary Immunodeficiency

Turkey

Clinical Trials on Primary Immunodeficiency Diseases (PID)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations